PAR 0.00% 27.5¢ paradigm biopharmaceuticals limited..

Ann: Phase 2 Synovial Fluid Biomarker Study Update, page-5

  1. 4,210 Posts.
    lightbulb Created with Sketch. 6686
    I wouldn't view it as all negative! Multicentre site means broadening of this study, this could play very well for us over the longer term.





    https://hotcopper.com.au/data/attachments/3725/3725481-2a6b0db89385e68b3338cd627aa6adf8.jpg
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.